Oncology Consultations®: Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases
Mark Agulnik, MD; Shaina A. Rozell, MD, MPH
Release Date: December 23, 2024
Expiration Date: December 23, 2025
Activity Overview
This Oncology Consultations® is a video-based program in which two experts use a case-based approach to discuss the treatment and management of epithelioid sarcoma. In this activity, the faculty focus on the current and emerging therapeutic strategies for the management of epithelioid sarcoma across lines of care. This engaging format is designed to help clinicians identify best practices in the diagnosis and management of epithelioid sarcoma and to improve outcomes for their patients with this rare soft tissue sarcoma subtype.
Target Audience
Oncologists, surgical oncologists, pediatric oncologists, pathologists, dermatologists, NPs, PAs, oncology nurses, pharmacists, patients and other HCPs involved in the care of patients with epithelioid sarcoma
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Identify epithelioid sarcoma through recognition of its unique features
- Recognize when to refer patients with epithelioid sarcoma to specialized academic centers and discuss the importance of clinical trials in developing and providing access to emerging therapies
Mark Agulnik, MD
Professor of Clinical Medicine
Vice Chair for Faculty Development, Department of Medicine
Section Chief of Sarcomas & Melanoma
Division of Medical Oncology, Department of Medicine
Keck School of Medicine of University of Southern California
Los Angeles, CA
Disclosures: Consultant: Aadi Bioscience, Boehringer Ingelheim, Daiichi Sankyo. Speaker: Deciphera.
Shaina A. Rozell, MD, MPH
Medical Oncology/Hematology
Director Hereditary Cancer Clinic
Affiliated Oncologists, LLC
Chicago, IL
Disclosures: Speaker: AstraZeneca, Daiichi Sankyo, Gilead.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.